1
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Re: “Oncology Drug Discovery and Clinical Trial Testing: Who's Listening?”

Pages 107-108 | Published online: 11 Jun 2009

References

  • Harding M J, Cantwell B MJ, Milstead R AV, et al. Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8- dideazafolic acid) in colorectal cancer. Br J Cancer 1988; 57: 628–629
  • Cantwell B MJ, Macaulay V, Harris A L, et al. Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB3717) in advanced breast cancer. Eur J Cancer Clin Oncol 1988; 24: 733–736
  • Cantwell B MJ, Earnshaw M, Harris A L. Phase II study of a novel antifolate, N10-propargyl-5,8-dideazafolic acid (CB3717), in ma- lignant mesothelioma. Cancer Treat Rep 1986; 70: 1335–1336
  • Bassendine M F, Curtin N J, Loose H, et al. Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study. J Hepatol 1987; 4: 349–356
  • Cantwell B MJ, Harris A L. The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8-dideazafolic acid). Br J Cancer 1988; 58: 189–190
  • Galivan J, Nimec Z, Rhee M. Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine. Cancer Res 1987; 47: 5256–5260

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.